The company's ARPOB per day rose to Rs 62,140 in Q2 FY25, a marginal growth of 1.9 per cent Y-o-Y compared to Rs 61,003 reported for the same period last year
Standalone health insurance provider Star Health and Allied Insurance Company has reported a profit after tax for the July-September 2024 quarter at Rs 111.29 crore, the company said. The city-based company registered a profit after tax of Rs 125.30 crore registered during the corresponding quarter of last year. For the six month period ending September 30, 2024, the profit after tax grew to Rs 430.21 crore, as against Rs 413.15 crore registered a year ago. The Gross Written Premium during the quarter under review grew to Rs 4,371.30 crore, from Rs 3,731.70 crore registered in the year ago period. For the six month period ending September 30, 2024, the Gross Written Premium surged to Rs 7,847.22 crore, from Rs 6,680.32 crore registered a year ago. The investment assets grew by 17.2 per cent and reached Rs 16,431 crore as on September 30, 2024, with an investment income of Rs 354 crore. The combined ratio in Q2FY25 stood at 103 per cent and 101 per cent in H1FY25, a company stateme
Punjab Health Minister Balbir Singh on Thursday refuted claims by the private hospitals that the state government owed over Rs 600 crore for various treatments availed under the Ayushman Bharat Mukh Mantri Sehat Bima Yojna. He said the total pending amount for both public and private hospitals is Rs 364 crore. Singh said the breakup of pending payments shows that Rs 166.67 crore are owed to the public hospitals and Rs 197 crore to the private hospitals. The minister's reaction came a day after the private hospitals and nursing association (PHANA) claimed that the state government owed over Rs 600 crore and had also threatened to stop providing medical treatments under the Ayushman Bharat Mukh Mantri Sehat Bima Yojana. Notably, the Ayushman Bharat Mukh Mantri Sehat Bima Yojana offers cashless treatment up to Rs 5 lakh per family per year in as many as 772 government and private empaneled hospitals across the state. The minister said since April 1, 2024, the government has disbursed
AstraZeneca's drug pipeline has evolved significantly under CEO Pascal Soriot since he took over more than a decade ago
The expected revenue growth in FY25 comes on the back of an estimated 14% growth in the last financial year
Robust growth in H1FY24 signals rebound in medical tourism, fuels bigger expectations
Surgery cost is found to be only 0.39 per cent of the total profit